TCM
ABBV icon

Tributary Capital Management’s AbbVie ABBV Stock Holding History

Tributary Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,805
Closed -$610K – 136
2026
Q1 		$610K Sell
2,805
-50
-2% -$11.1K 0.06% 105
2025
Q4 		$652K Sell
2,855
-105
-4% -$23.9K 0.06% 107
2025
Q3 		$685K Sell
2,960
-90
-3% -$18.3K 0.06% 103
2025
Q2 		$566K Buy
+3,050
New +$567K 0.05% 116

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tributary Capital Management's ABBV Position: Q2 2026 in Review

Tributary Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 2,805 shares — an estimated $610K sold.

Tributary Capital Management first reported a position in ABBV in Q2 2025 and held it in 4 quarters. The position peaked at $685K in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Tributary Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Tributary Capital Management sold 2,805 AbbVie shares in Q2 2026, an estimated $610K.
  • Tributary Capital Management first reported a position in AbbVie in Q2 2025 and held it in 4 quarters.
  • Tributary Capital Management's AbbVie position peaked at $685K in Q3 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Tributary Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.